Get the Daily Brief
Latest Biotech News
Cancer Chemotherapy Resistance Biomarkers Show Promise
New research led by the Spanish National Cancer Research Centre and University of Cambridge, in collaboration with startup Tailor Bio, has developed genomic tests using chromosomal instability...
Breakthroughs in Alzheimer’s and Neurodegenerative Research
Recent studies have further elucidated the molecular underpinnings of Alzheimer’s disease and neurodegeneration. Weill Cornell researchers demonstrated that a rare APOE3 Christchurch gene mutation...
Innovations in CAR-T and Cell Therapy Expanding Treatment Reach
CAR-T cell therapy continues to evolve with next-generation constructs designed to overcome tumor heterogeneity and immunosuppressive microenvironments. Multi-targeting CAR-T cells and engineered...
Agricultural and Environmental Biotech Research Highlights
Several studies emphasize innovations addressing agricultural resilience and environmental sustainability. USDA-funded research investigates Hurricane Helene’s flood sediment impacts on Tennessee...
Oncology Advances Spotlight: Roche and Exelixis Lead Trials
Robust clinical trial data underscore progress in oncology. Roche’s Phase 3 Sunmo trial shows that combining bispecific antibody Lunsumio with ADC Polivy substantially outperforms standard chemo...
AI’s Expanding Role in Climate and Healthcare Data Management
Artificial intelligence continues to promise transformative impacts across sectors. Research published by the Grantham Research Institute predicts AI-enabled technologies could reduce global...
Orcas Use Kelp as Grooming Tools in Social Behavior
Recent drone footage in the Salish Sea has revealed that southern resident killer whales engage in tool use by breaking off bull kelp stalks to groom themselves and close pod-mates. This novel...
Illumina’s Strategic Acquisition of SomaLogic in Proteomics
Illumina has agreed to acquire SomaLogic and related assets from Standard BioTools for up to $425 million, reinforcing its commitment to expanding proteomics capabilities and multiomics...
Exelixis Advances Colorectal Cancer Therapy with Phase 3 Gains
Exelixis’ experimental drug zanzalintinib combined with Roche’s checkpoint inhibitor Tecentriq demonstrated a significant overall survival improvement versus Bayer’s Stivarga in a pivotal Phase 3...
Novo Nordisk Ends Partnership with Hims Over Compounded Obesity Drugs
Novo Nordisk has terminated its marketing deal with telehealth company Hims & Hers, citing unlawful mass compounding and deceptive marketing of its obesity treatment Wegovy. The partnership,...
Breakthrough Genetic Test Predicts Chemotherapy Resistance in Cancer
Researchers at the University of Cambridge, Spanish National Cancer Research Centre (CNIO), and biotech startup Tailor Bio have developed an innovative genomic assay capable of forecasting cancer...
Advances in CAR-T Cell Therapy Address Tumor Microenvironment Challenges
Recent innovations in CAR-T therapy for lymphoma leverage engineered T cells with enhanced capabilities to overcome tumor heterogeneity, the immunosuppressive microenvironment, and T cell...
Formation Bio’s €545M Sanofi Deal Fuels JAK/SYK Inhibitor Development
AI-driven biotech Formation Bio signed a licensing agreement potentially worth €545 million with Sanofi for its dual JAK/SYK inhibitor gusacitinib. While gusacitinib is in Phase 3 for chronic hand...
Compass Pathways Reports Phase 3 Psilocybin Benefit in Depression
Compass Pathways achieved its primary endpoint in the largest phase 3 study of psilocybin for treatment-resistant depression, demonstrating a statistically significant reduction in depressive...
Leap Therapeutics Cuts 75% Workforce, Ends Sole Clinical Trial
Leap Therapeutics deepened restructuring by expanding layoffs to cover 75% of staff and terminating development of its only clinical-stage asset, sirexatamab, an anti-DKK1 antibody for cancer....
Synthetic Biology Turns Plastic Waste into Painkillers
Scientists at the University of Edinburgh engineered bacteria to convert recycled plastic waste into pharmaceutical compounds, including the widely used analgesic paracetamol. By exploiting a...
FDA Leadership Shakeup: Acting CDER Chief Exits Amid Agency Turmoil
Jacqueline Corrigan-Curay, acting director of the FDA's Center for Drug Evaluation and Research (CDER), announced her retirement effective July 2025. Her departure adds to a wave of senior staff...
Illumina's Strategic Acquisition: SomaLogic Proteomics Assets Bolster Multiomics
Illumina announced its acquisition of proteomics technology assets originally developed by SomaLogic from Standard BioTools for a deal valued up to $425 million, including upfront cash,...
Precision Genomics Partnership Targets Cardiovascular and Cancer Risk Assessment
Galatea Bio and Fabric Genomics have entered a strategic partnership to develop genetic disease risk assays integrating polygenic risk scores (PRS) with clinical gene panel interpretation....
Breakthrough Test Predicts Chemotherapy Resistance via Chromosomal Instability Signatures
Researchers at the University of Cambridge, Spanish National Cancer Research Centre, and Tailor Bio have developed a genomic test that predicts resistance to chemotherapy in diverse cancer...